Protocol Ledger

NCT07508787 · Phase II · RECRUITING

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Interventional Phase II clinical trial protocol NCT07508787 sponsored by Nefro Avillion Clinical Development in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-29 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07508787
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07508787
Protocol FieldVerified Registry Value
NCT IdentifierNCT07508787
Consolidated Lead SponsorNefro Avillion Clinical Development
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2026-06-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI